Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

JHJaguar Health, Inc.

35 indications, side-by-side phase, drug & LoA

$2.69

-0.12 (-4.44%)

C 42Pipeline Score Undervalued Pharma · Clinical
Market Cap
1.17 M
EPS
-708.72
P/E Ratio
-
Value Trade
142.75 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    20.27 M

  • R&D Expenses

    3.93 M

  • Operating CF

    8.83 M

  • Total Assets

    37.43 M

  • Total Liabilities

    53.19 M

  • Equity

    -15.75 M

  • D/E Ratio

    12,345

-23.22 %
Week
-79.23 %
1 Month
-86.92 %
3 Month
-93.19 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Profitable

  • Cash Position

    7.28 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 20, 2026
Overview
Volume
56.66 K
52 Week Range
2.53 - 171.50
% held by Insiders
17.77 %
% held by Institutions
1.22 %
Enterprise Value
23.84 M
Total Shares
14.04 M
Short %
0.52 %
Float Shares
12.41 M
Company Description
HQ: 200 PINE STREET SUITE 400, SAN...
Employees:47
http://www.jaguar.health

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C42
Pipeline Score
$18M
Pipeline Value
Undervalued
Valuation Signal
2
Drugs Scored
15.0x
rNPV / MCap
Top 63%
Micro Cap
(rank 336 of 905)
Percentile Rank
Jaguar Health, Inc. carries a moderate pipeline score (42/100), with $1.0B risk-adjusted pipeline value, led by Crofelemer in Cancer Therapy-Related Diarrhea (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Crofelemer
Small molecule		Cancer Therapy-Related DiarrheaPhase 3NCT0453862546% $980M COMPLETED 287 - -Oct 30, 2023 -Jul 26, 2024
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
crofelemer
microvillus inclusion disease (MVID),short bowel syndrome (SBS-IF)
Phase 2
2025-06-23
crofelemer
microvillus inclusion disease (MVID),short bowel syndrome (SBS-IF)
Phase 2
2025-06-23
crofelemer
microvillus inclusion disease (MVID),short bowel syndrome (SBS-IF)
Phase 2
2025-06-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in JAGX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
JAGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
JAGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
JAGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
JAGX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
JAGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Jaguar Health, Inc. (JAGX) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How JAGX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Short Bowel Syndrome #2 of 3 PHASE 2 Crofelemer for
TAK SNN
$1.64B 0 CONTENDER
Rare Genetic Disorders #38 of 61 PHASE 2 Crofelemer for
BMRN ASND NVS
—0.76 FOLLOWER